Tag Archives: SPRO
Oppenheimer Believes Spero Therapeutics (NASDAQ: SPRO) Won’t Stop Here
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $19.00. The company’s shares closed last Friday at $14.02, close to its 52-week high of $14.60. According to
Spero Therapeutics (SPRO) Receives a Buy from Oppenheimer
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $12.45. According to TipRanks.com, DeGeeter is a
Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (NASDAQ: SPRO) and Eiger Biopharmaceuticals (NASDAQ: EIGR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spero Therapeutics (SPRO – Research Report) and Eiger Biopharmaceuticals (EIGR – Research Report) with bullish sentiments. Spero Therapeutics (SPRO) In a report
Spero Therapeutics (SPRO) Gets a Buy Rating from Oppenheimer
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $20.00. The company’s shares closed last Monday at $5.35, close to its 52-week low of
Spero Therapeutics (SPRO) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $8.89, close to its 52-week low of $7.99. According
Spero Therapeutics (SPRO) Receives a Buy from Cowen & Co.
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Spero Therapeutics (SPRO – Research Report). The company’s shares closed last Monday at $10.71. According to TipRanks.com, Baral is a 5-star analyst with an
